lnsights into Adjuvant Systemic Treatment Selection for Patients with Stage III Melanoma: Data from the Dutch Cancer Registry

Aldenhoven, Loeki

DOI: https://doi.org/10.1007/s11523-024-01090-9

2024-08-26

Targeted Oncology

Abstract:Patient demographics and shared decision making might influence the choice of adjuvant therapy for stage III melanoma.

oncology

What problem does this paper attempt to address?

Assessing the use of anti-PD1 monotherapy as adjuvant therapy and determinants of treatment choice in stage III cutaneous melanoma in the US

Eric D. Whitman,Todor I. Totev,Shan Jiang,Wilson L. da Costa,Dmitri Grebennik,Hongjue Wang,Andra-Ecaterina Boca,Rajeev Ayyagari

DOI: https://doi.org/10.1186/s12885-024-12178-w

IF: 4.638

2024-03-29

BMC Cancer

Abstract:The objective of this study was to describe real-world adjuvant therapy (AT) use by disease substage and assess determinants of treatment choice among patients with stage III melanoma.

oncology
Disparities in Receipt of Adjuvant Immunotherapy among Stage III Melanoma Patients

Kathleen M. Mulligan,Hanna Kakish,Omkar Pawar,Fasih Ali Ahmed,Mohamedraed Elshami,Luke D. Rothermel,Jeremy S. Bordeaux,Iris Y. Sheng,Ankit Mangla,Richard S. Hoehn

DOI: https://doi.org/10.1097/coc.0000000000001117

2024-06-28

American Journal of Clinical Oncology

Abstract:Objectives: Melanoma survival has greatly improved with the advent of immunotherapy, but unequal access to these medications may exist due to nonmedical patient factors such as insurance status, educational background, and geographic proximity to treatment. Methods: We used the National Cancer Database to assess patients with nonmetastatic cutaneous melanoma who underwent surgical resection and sentinel lymph node biopsy (SLNB) with tumor involvement from 2015 to 2020. We evaluated rates of adjuvant immunotherapy among this patient population based on patient, tumor, and facility variables, including insurance status, socioeconomic status, pathologic stage (IIIA-IIID), and treatment facility type and volume. Results: Adjuvant immunotherapy was associated with improved survival for stage III melanoma, with a slight increase in 5-year OS for stage IIIA (87.9% vs. 85.9%, P=0.044) and a higher increase in stages IIIB-D disease (70.3% vs. 59.6%, P<0.001). Receipt of adjuvant immunotherapy was less likely for patients who were older, low socioeconomic status, or uninsured. Low-volume and community cancer centers had higher rates of adjuvant immunotherapy overall for all stage III patients, whereas high-volume and academic centers used adjuvant immunotherapy much less often for stage IIIA patients compared with those in stages IIIB-D. Conclusions: Our results demonstrate inconsistent use of adjuvant immunotherapy among patients with stage III melanoma despite a significant association with improved survival. Notably, there was a lower use of adjuvant immunotherapy in patients of lower SES and those treated at high-volume centers. Equity in access to novel standards of care represents an opportunity to improve outcomes for patients with melanoma.

oncology
Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy

Thomas M Atkinson,Jennifer L Hay,Soo Young Kim,Elizabeth Schofield,Michael A Postow,Parisa Momtaz,Allison Betof Warner,Alexander N Shoushtari,Margaret K Callahan,Jedd D Wolchok,Yuelin Li,Paul B Chapman

DOI: https://doi.org/10.1093/oncolo/oyac266

2023-04-06

Abstract:Background: Adjuvant anti-PD1 treatment improves relapse-free survival (RFS) but has not been shown to improve overall survival (OS) in melanoma and is associated with risks of immune-related adverse events (irAEs), some permanent. We identified factors patients consider in deciding whether to undergo adjuvant anti-PD1 treatment and assessed prospective health-related quality of life (HRQoL), treatment satisfaction, and decisional regret. Patients and methods: Patients with stage IIIB-IV cutaneous melanoma and free of disease, were candidates for adjuvant anti-PD1 immunotherapy, and had not yet discussed adjuvant treatment options with their oncologist were eligible. Participants viewed a 4-minute informational video tailored to their disease stage which communicated comprehensive, quantitative information about the risk of relapse both with and without adjuvant treatment, and risks of each irAE before deciding whether or not to opt for adjuvant therapy. We collected data on demographics, HRQoL, and attitudes toward adjuvant treatment over 1 year. Results: 14/34 patients (41%) opted for adjuvant anti-PD1 immunotherapy, 20/34 (59%) opted for observation. Patients choosing adjuvant immunotherapy scored higher on HRQoL social well-being at pre-treatment, were more likely to endorse positive statements about adjuvant immunotherapy, and to perceive that their physician preferred adjuvant therapy. They had lower decisional regret and higher satisfaction, even if they experienced toxicity or recurrence. Conclusions: When provided with comprehensive quantitative information about risks and benefits of adjuvant anti-PD1 immunotherapy, 20/34 (59%) of patients opted for observation. Patients choosing adjuvant immunotherapy had lower decisional regret and higher satisfaction over time even if they had poorer outcomes in treatment.
From decision to reflection: understanding the experiences and unmet care needs of patients treated with immunotherapy for melanoma in the adjuvant or metastatic setting

Nadia C.W. Kamminga,Astrid A.M. van der Veldt,Marlies Wakkee,Fauve R. van den Berge,Lianne A.A. van der Beek,Margot C.W. Joosen,Arjen Joosse,Karlijn de Joode,Tamar E.C. Nijsten,Marjolein Lugtenberg

DOI: https://doi.org/10.1186/s12885-024-12410-7

IF: 4.638

2024-05-31

BMC Cancer

Abstract:Despite increased use of immune checkpoint inhibitors (ICIs) in patients with advanced melanoma, little is known about patient experiences during this treatment. This study aimed to gain an in-depth understanding of experiences and unmet care needs of patients treated in the adjuvant or metastatic setting for advanced melanoma regarding their ICI treatment trajectory.

oncology
Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry

A Özkan,E Kapiteijn,F van den Bos,M J B Aarts,F W P J van den Berkmortel,C U Blank,M Bloem,W A M Blokx,M J Boers-Sonderen,J J Bonenkamp,A J M van den Eertwegh,J W B de Groot,J B Haanen,C E Holtslag,G A P Hospers,D Piersma,R S van Rijn,A M Stevense-den Boer,K P M Suijkerbuijk,A A M van der Veldt,G Vreugdenhil,M W J M Wouters,J E A Portielje,N A de Glas

DOI: https://doi.org/10.1016/j.ejca.2024.115056

Abstract:Background: Adjuvant anti-PD-1 therapy improves relapse free survival in stage III melanoma, but also leads to immune-related adverse events (irAEs). Older patients are of particular interest due to comorbidities and frailty, which may impact their ability to tolerate irAEs and benefit from anti-PD-1 therapy. This study aimed to explore associations between clinical parameters and the occurrence of grade ≥ 3 irAEs and recurrence-free survival (RFS) in older patients with radically resected stage III/IV cutaneous melanoma treated with adjuvant anti-PD-1 therapy. Methods: Patients aged ≥ 65 with resected stage III/IV cutaneous melanoma treated with adjuvant anti-PD-1 therapy between 2018 and 2022 were selected using real-world data from the nationwide Dutch Melanoma Treatment Registry (DMTR). A univariate and multivariable logistic regression was used to compare determinants of grade ≥ 3 irAEs, and univariate and multivariable Cox-proportional hazard models were fitted to identify factors influencing RFS. Results: The study included 885 patients, with 280 aged 75 and older. The incidence of grade ≥ 3 irAEs was 15.5 % in the 65-74 age group and 13.9 % in the ≥ 75 age group. No significant correlation was found between age and grade ≥ 3 irAEs. However, an increasing number of comorbidities was associated with a higher risk of grade ≥ 3 irAEs (multivariable analyses: OR 1.83, 95 % C.I. 0.99-3.40). The 1-year RFS rate of 80.0 % of this study was comparable to those reported in previous registration trials and real-world data. Having ≥ 3 comorbidities was significantly associated with a decrease in RFS (HR: 1.68, 95 % C.I. 1.15-2.44). Conclusion: Older patients had similar benefit of adjuvant immunotherapy compared to older subgroups in previous trials. However, patients with multiple comorbidities were at increased risk of grade ≥ 3 irAEs and had a lower RFS. This should be considered when deciding upon adjuvant treatment.
Treatment of Stage III Resectable Melanoma—Adjuvant and Neoadjuvant Approaches

Ahmad A. Tarhini,Ella Castellano,Islam Eljilany

DOI: https://doi.org/10.1097/ppo.0000000000000706

2024-03-27

The Cancer Journal

Abstract:Patients with stage III resectable melanoma carry a high risk of melanoma recurrence that ranges from approximately 40% to 90% at 5 years following surgical management alone. Postoperative systemic adjuvant therapy targets residual micrometastatic disease that could be the source of future recurrence and death from melanoma. Randomized phase III adjuvant trials reported significant improvements in overall survival with high-dose interferon α in 2 of 3 studies (compared with observation and GMK ganglioside vaccine) and with anti–cytotoxic T-lymphocyte antigen 4 ipilimumab at 10 mg/kg compared with placebo and ipilimumab 3 mg/kg compared with high-dose interferon α. In the modern era, more recent phase III trials demonstrated significant recurrence-free survival improvements with anti–programmed cell death protein 1, pembrolizumab, and BRAF-MEK inhibitor combination dabrafenib-trametinib (for BRAF mutant melanoma) versus placebo. Furthermore, anti–programmed cell death protein 1, nivolumab and pembrolizumab have both been shown to significantly improve recurrence-free survival as compared with ipilimumab 10 mg/kg. For melanoma patients with clinically or radiologically detectable locoregionally advanced disease, emerging data support an important role for preoperative systemic neoadjuvant therapy. Importantly, a recent cooperative group trial (S1801) reported superior event-free survival rates with neoadjuvant versus adjuvant therapy. Collectively, current data from neoadjuvant immunotherapy and targeted therapy trials support a future change in clinical practice in favor of neoadjuvant therapy for eligible melanoma patients.

oncology
Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe

Michael Weichenthal,Joanna Mangana,Iva Gavrilova,Iwona Lugowska,Gergana Krumova Shalamanova,Lidija Kandolf,Vanna Chiarion-Sileni,Peter Mohr,Teodora Sotirova Karanikolova,Pawel Teterycz,Enrique Espinosa,Philipp Schnecko,Phil Cheng,Marc Bender,Shan Jiang,Thomas Burke,Paolo Antonio Ascierto,Helen Gogas,Ivan Marquez Rodas,Piotr Rutkowski,Dirk Schadendorf,Reinhard Dummer,for the EUMelaReg Consortium

DOI: https://doi.org/10.3390/cancers16213558

2024-10-23

Cancers

Abstract:Background: Although data on patients treated with pembrolizumab are available from clinical trials and single-country real-world reports, to our knowledge no multi-country real-world studies have investigated the use of pembrolizumab as an adjuvant treatment for stage III melanoma. Methods: We used the European Melanoma Registry (EUMelaReg), a disease entity-based registry specific for melanoma, to examine treatment and outcomes for adult patients with stage III melanoma with lymph node involvement who had complete resection and received adjuvant treatment with pembrolizumab. The primary objectives were to describe the demographic and clinical characteristics of the included patients as well as time on adjuvant pembrolizumab treatment (TOT), real-world recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) from adjuvant pembrolizumab initiation. Secondary objectives were time to next treatment (TTNT) after adjuvant use of pembrolizumab, next-line therapy for stage III and unresectable stage IV melanoma and overall survival (OS) from initiation of pembrolizumab. Results: Patients were stratified according to age, sex, BRAF status, number of positive lymph nodes and disease substage. Median TOT was 11.1 (9.2–11.5) months, median RFS was 29.6 [18.7–not reached (NR)] months and median DMFS was 32.4 (22.7–NR) months. TTNT was 29.9 (22.2–NR) months, while median OS was not reached. Conclusions: The results of this study offer insights into the real-world use of pembrolizumab as an adjuvant therapy for melanoma in Europe.

oncology
The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma; An Australian Cohort

Lisanne P Zijlker,Henry Chen,Andrew J Spillane,Maria Gonzalez,Thomas E Pennington,Alexander M Menzies,Serigne N Lo,Peter Ferguson,Robert Rawson,Andrew J Colebatch,Jonathan R Stretch,John F Thompson,Sydney Ch'ng,Omgo Nieweg,Kerwin F Shannon,Georgina V Long,Richard A Scolyer,Robyn P M Saw,Alexander C J van Akkooi

DOI: https://doi.org/10.1245/s10434-024-15274-0

Abstract:Background: Neoadjuvant systemic therapy (NAST) for patients with stage III melanoma achieves high major pathologic response rates and high recurrence-free survival rates. This study aimed to determine how NAST with targeted therapies (TTs) and immune checkpoint inhibitors (ICIs) influences surgical outcomes after lymph node dissection in terms of complications, morbidity, and textbook outcomes. Methods: Patients who underwent a lymph node dissection after either NAST in a clinical trial or upfront surgery for stage III melanoma between 2014 and 2022 were identified from an institutional research database. Results: The study included 89 NAST-treated patients and 79 upfront surgery-treated patients. The rate of postoperative complications did not differ between the NAST- and upfront surgery-treated patients (55% vs. 51%; p = 0.643), and steroid treatment for drug toxicity did not influence the complication rate (odds ratio [OR], 1.1; 95% confidence interval [CI], 0.4-3; p = 0.826). No significant differences in postoperative morbidity were observed in terms of seroma (23% vs. 11%; p = 0.570) or lymphedema (36% vs. 51%; p = 0.550). The rate of achieving a textbook outcome was comparable for the two groups (61% vs. 57%; p = 0.641). Conclusions: The surgical outcomes after lymph node dissections were comparable between the patients who received NAST and those who had upfront surgery, indicating that surgery can be safely performed after NAST with TT or ICI for stage III melanoma.
Sequencing of Immunotherapy and Outcomes in Operable Clinical Stage III Melanoma: A National Cohort Study

Anushka Dheer,Gabriella N. Tortorello,Neha Shafique,Mohammad S. Farooq,Tara C. Mitchell,Xiaowei Xu,John T. Miura,Giorgos C. Karakousis

DOI: https://doi.org/10.1002/jso.27933

2024-10-05

Journal of Surgical Oncology

Abstract:Background and Objectives The impact of neoadjuvant immunotherapy (NIT) on overall survival (OS) in patients with resectable stage III melanoma remains unknown. We sought to identify factors associated with receipt of NIT and survival outcomes in patients with clinical stage III melanoma undergoing surgery. Methods The National Cancer Database (2016–2020) was used to identify patients with clinical stage III melanoma who underwent surgery and received either NIT or adjuvant immunotherapy (AIT) only. Multivariable regression, Kaplan–Meier, and Cox proportional hazard methods were used to analyze variables of interest. Results Patients with clinical N3 disease had 2.5 times the odds of NIT compared to those with N1 disease (95% CI 1.74–3.49). There was no difference in 3‐year OS between the two cohorts: 79% (95% CI 73%–85%) for NIT patients and 75% (95% CI 73%–76%) for AIT patients (p = 0.078). Patients with N2/N3 disease had improved 3‐year OS of 79% with NIT versus 71% for AIT‐only (HR 0.61, 95% CI 0.38–0.97, p = 0.037). Conclusions NIT is given more selectively to clinical stage III patients with more advanced N category disease. Despite significant differences in N category between groups, there was no difference in OS observed at 3 years, and NIT was associated with a survival advantage among N2/N3 patients.

oncology,surgery
Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial

Kalijn F. Bol,Gerty Schreibelt,Martine Bloemendal,Wouter W. van Willigen,Simone Hins-de Bree,Anna L. de Goede,Annemiek J. de Boer,Kevin J. H. Bos,Tjitske Duiveman-de Boer,Michel A. M. Olde Nordkamp,Tom G. M. van Oorschot,Carlijn J. Popelier,Jeanne M. Pots,Nicole M. Scharenborg,Mandy W. M. M. van de Rakt,Valeska de Ruiter,Wilmy S. van Meeteren,Michelle M. van Rossum,Sandra J. Croockewit,Bouke J. Koeneman,Jeroen H. A. Creemers,Inge M. N. Wortel,Caroline Angerer,Mareke Brüning,Katja Petry,Andrzej Dzionek,Astrid A. van der Veldt,Dirk J. van Grünhagen,Johanna E. M. Werner,Johannes J. Bonenkamp,John B. A. G. Haanen,Marye J. Boers-Sonderen,Rutger H. T. Koornstra,Martijn F. Boomsma,Erik H. J. Aarntzen,Martin Gotthardt,James Nagarajah,Theo J. M. de Witte,Carl G. Figdor,Johannes H. W. de Wilt,Johannes Textor,Jan Willem B. de Groot,Winald R. Gerritsen,I. Jolanda M. de Vries

DOI: https://doi.org/10.1038/s41467-024-45358-0

IF: 16.6

2024-02-23

Nature Communications

Abstract:Abstract Autologous natural dendritic cells (nDCs) treatment can induce tumor-specific immune responses and clinical responses in cancer patients. In this phase III clinical trial (NCT02993315), 148 patients with resected stage IIIB/C melanoma were randomized to adjuvant treatment with nDCs ( n = 99) or placebo ( n = 49). Active treatment consisted of intranodally injected autologous CD1c+ conventional and plasmacytoid DCs loaded with tumor antigens. The primary endpoint was the 2-year recurrence-free survival (RFS) rate, whereas the secondary endpoints included median RFS, 2-year and median overall survival, adverse event profile, and immunological response The 2-year RFS rate was 36.8% in the nDC treatment group and 46.9% in the control group ( p = 0.31). Median RFS was 12.7 months vs 19.9 months, respectively (hazard ratio 1.25; 90% CI: 0.88−1.79; p = 0.29). Median overall survival was not reached in both treatment groups (hazard ratio 1.32; 90% CI: 0.73−2.38; p = 0.44). Grade 3−4 study-related adverse events occurred in 5% and 6% of patients. Functional antigen-specific T cell responses could be detected in 67.1% of patients tested in the nDC treatment group vs 3.8% of patients tested in the control group (p < 0.001). In conclusion, while adjuvant nDC treatment in stage IIIB/C melanoma patients generated specific immune responses and was well tolerated, no benefit in RFS was observed.

multidisciplinary sciences
Should I Have Adjuvant Immunotherapy? An Interview Study Among Adults with Resected Stage 3 Melanoma and Their Partners

Ann Livingstone,Donna Milne,Kathy Dempsey,Danielle Marie Muscat,Alexander M. Menzies,Kirsten Howard,Martin R. Stockler,Rachael L. Morton

DOI: https://doi.org/10.1007/s40271-021-00507-1

2021-03-24

Abstract:Adjuvant immunotherapy is a new treatment paradigm for adults with resected stage 3 melanoma. However, therapy can lead to long-term adverse health impacts, making immunotherapy decisions difficult. This study aimed to explore patients and their partners' views when considering whether to commence adjuvant immunotherapy.
Adjuvant Therapy for High-Risk Stage II Melanoma: Current Paradigms in Management and Future Directions

Gracia Maria Vargas,Mohammad Saad Farooq,Giorgos C Karakousis

DOI: https://doi.org/10.3390/cancers16152690

2024-07-29

Abstract:Melanoma is the fifth most common cancer in the United States and accounts for the majority of all skin cancer-related deaths, making it the most lethal cutaneous malignancy. Systemic adjuvant therapy for stage IIB-IV melanoma is now approved for patients who have undergone surgical resection, given the appreciable risk of recurrence and mortality in this patient population. Despite the lower stage, high-risk stage II melanoma (stage IIB/IIC) can often exhibit an even more aggressive course when compared to stage IIIA/IIIB disease, thus justifying consideration of adjuvant therapy in these patients. In this review, we highlight the current standard of practice for the treatment of stage IIB/C melanoma, with a focus on adjuvant therapies supported by published landmark clinical trials, including anti-PD-1 therapy. Notably, adjuvant therapies approved thus far in this patient population have demonstrated an improvement in recurrence-free survival, while their impact on overall survival is pending. Finally, this review highlights currently ongoing trials and future directions for research and treatment possibilities for high-risk clinical stage II melanoma.
Immunotherapy utilization in stage IIIA melanoma: less may be more

Alexander E. Frey,Daniel M. Kerekes,Sajid A. Khan,Thuy T. Tran,Harriet M. Kluger,James E. Clune,Stephan Ariyan,Mario Sznol,Jeffrey J. Ishizuka,Kelly L. Olino

DOI: https://doi.org/10.3389/fonc.2024.1336441

IF: 4.7

2024-02-07

Frontiers in Oncology

Abstract:Background: Immunotherapy agents are approved for adjuvant treatment of stage III melanoma; however, evidence for survival benefit in early stage III disease is lacking. Current guidelines for adjuvant immunotherapy utilization in stage IIIA rely on clinician judgment, creating an opportunity for significant variation in prescribing patterns. This study aimed to characterize current immunotherapy practice variations and to compare patient outcomes for different prescribing practices in stage IIIA melanoma. Study design: Patients with melanoma diagnosed from 2015-2019 that met American Joint Committee on Cancer 8th edition criteria for stage IIIA and underwent resection were identified in the National Cancer Database. Multiple imputation by chained equations replaced missing values. Factors associated with receipt of adjuvant immunotherapy were identified. Multivariable Cox proportional hazards regression compared overall survival across groups. Results: Of 4,432 patients included in the study, 34% received adjuvant immunotherapy. Patients had lower risk-adjusted odds of receiving immunotherapy if they were treated at an academic center (OR=0.48, 95%CI=0.33-0.72, p<0.001 vs. community facility) or at a high-volume center (OR=0.69, 0.56-0.84, p<0.001 vs. low-volume). Immunotherapy receipt was not associated with risk-adjusted survival (p=0.095). Moreover, patients treated at high-volume centers experienced longer overall risk-adjusted survival than those treated at low-volume centers (HR=0.52, 0.29-0.93, p=0.030). Risk-adjusted survival trended toward being longer at academic centers than at community centers, but the difference was not statistically significant. Conclusion: Academic and high-volume centers utilize significantly less adjuvant immunotherapy in stage IIIA melanoma than community and low-volume centers without compromise in overall survival. These findings suggest that this population may benefit from more judicious immunotherapy utilization.

oncology
Influence of adjuvant therapies on organ-specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg

Sebastian A Wohlfeil,Leonie Kranzmann,Christel Weiß,Imke von Wasielewski,Kai C Klespe,Katharina C Kähler,Michael Weichenthal,Dirk Schadendorf,Lisa Zimmer,Peter Mohr,Friedegund Meier,Claudia Pfoehler,Carola Berking,Markus V Heppt,Rudolf Herbst,Alexander Kreuter,Ralf Gutzmer,Jens Ulrich,Frank Meiss,Christoffer Gebhardt,Edgar Dippel,Ulrike Leiter,Bastian Schilling,Selma Ugurel,Jochen Utikal

DOI: https://doi.org/10.1002/ijc.35078

2024-11-15

Abstract:This study investigated whether adjuvant treatments in stage III cutaneous melanoma (CM) influenced patterns of recurrence. Patients with primary (n = 1033) or relapsed CM (n = 350) who received adjuvant therapies with Nivolumab (N), Pembrolizumab (P), or Dabrafenib and Trametinib (D + T) were extracted from the prospective multicenter real-world skin cancer registry ADOReg. Endpoints were progression-free survival (PFS), distant metastasis-free survival (DMFS), organ-specific DMFS, and overall survival (OS). For primary cases, D + T indicated an improved PFS (1- and 2-year PFS: 90.9%; 82.7%) as compared to P (81.0%, 73.9%; p = .0208), or N (83.8%, 75.2%; p = .0539). BRAF-mutated(mut) CM demonstrated significantly lower PFS (p = .0022) and decreased DMFS (p = .0580) when treated with immune checkpoint inhibitor (ICI) instead of D + T. Besides, NRAS-mut CM tended to perform worse than wt CM upon ICI (PFS: p = .1349; DMFS: p = .0540). OS was similar between the groups. Relapsed cases showed decreased PFS, DMFS, and OS in comparison to primary (all: p < .001), without significant differences between the subgroups. Organ-specific DMFS was significantly altered for primary cases with bone (p = .0367) or brain metastases (p = .0202). In relapsed CM, the frequency of liver (D + T: 1.5%; P: 12%; N: 9%) and LN metastases (D + T: 1.5%; P: 12%; N: 10.2%) was significantly lower with adjuvant D + T than ICI. NRAS-mut CM showed increased recurrence in primary and relapsed cases. These data show that adjuvant D + T is superior to ICI in primary BRAF-mut CM.
Real‐world outcomes of patients with resected stage III melanoma treated with adjuvant therapies

Danai Dima,Nerea Lopetegui‐Lia,Olisaemeka Ogbue,Bennett Osantowski,Fauzia Ullah,Xuefei Jia,Jung Min Song,Brian Gastman,James Isaacs,Lucy Boyce Kennedy,Pauline Funchain

DOI: https://doi.org/10.1002/cam4.7257

IF: 4.711

2024-06-22

Cancer Medicine

Abstract:Both immunotherapy and targeted therapy are used as adjuvant treatment modalities for stage III melanoma. However, data describing real‐world outcomes are limited. Our study aimed to assess the efficacy and safety of adjuvant anti‐PD‐1 immunotherapy and targeted therapy in a real‐world cohort of 130 patients with resected stage III melanoma, and further delineate patterns of recurrence and treatment strategies. Background Both immunotherapy (IO) and targeted therapy (TT) are used as adjuvant (adj) treatment for stage III melanoma, however, data describing real‐world outcomes are limited. In addition, a significant proportion of patients relapse, for whom best management is unclear. The aim of our study was to assess the efficacy, and safety of adj anti‐PD1 IO and TT in a real‐world cohort of patients with resected stage III melanoma, and further delineate patterns of recurrence and treatment strategies. Methods We retrospectively analyzed 130 patients who received adj therapy (100 anti‐PD1 IO and 30 TT). Results At a median follow‐up of 30 months, median relapse‐free survival (RFS) was 24.6 (95% CI, 17–not reached [NR]) versus 64 (95% CI, 29.5–NR) months for the TT and IO groups, respectively (p = 0.26). Median overall survival (OS) was NR for either subgroup. At data cutoff, 77% and 82% of patients in TT and IO arms were alive. A higher number of grade ≥3 treatment‐related adverse events (AEs) were noted in the IO group (11% vs. 3%), however, a higher proportion of patients permanently discontinued adj therapy in the TT group (43% vs. 11%) due to toxicity. Strategies at relapse and outcomes were variable based on location and timing of recurrence. A significant number of patients who relapsed after adj IO received a second round of IO. Among them, patients who were off adj IO at relapse had superior second median RFS (mRFS2), compared to those who relapsed while on adj IO; mRFS2 was NR versus 5.1 months (95% CI, 2.5–NR), respectively, p = 0.02. Conclusion In summary, both TT and IO yielded prolonged RFS in a real‐world setting, however, longer follow‐up is needed to determine any potential OS benefit. Adj therapy, particularly TT, may not be as well tolerated as suggested in clinical trials, with lower completion rates (59% vs. 74%) in a real‐life setting. Overall, patients who relapse during adj therapy have poor outcomes, while patients who relapse after discontinuation of adj IO therapy appear to benefit from IO re‐treatment.

oncology
Information and communication priorities of patients and healthcare professionals in shared decision making regarding adjuvant systemic breast cancer treatment: A survey study

Olga C. Damman,Inge S. van Strien-Knippenberg,Ellen G. Engelhardt,Domino Determann D,Martine C. de Bruijne M,Sabine Siesling,Inge R. Konings,Danielle R. Timmermans

DOI: https://doi.org/10.1016/j.ejon.2024.102574

IF: 2.8

2024-04-12

European Journal of Oncology Nursing

Abstract:Purpose To assess information and communication priorities of patients and healthcare professionals in Shared Decision Making about adjuvant systemic treatment of primary breast cancer and identify key decision-relevant information accordingly. Methods Patients (N = 122) and professionals working with breast cancer patients (N = 118), of whom 38 were nurse practitioners and 32 nurses, were recruited using convenience sampling, and surveyed about information/communication aspects key to decision-making, using ranking assignments. We further posed a simple open question, questions about receiving population-based statistics versus personalized statistics concerning treatment outcomes, and their attitude and experience concerning Shared Decision Making. Data were analyzed using descriptive analysis and a qualitative analysis. Results Both patients and professionals prioritized information about treatment outcomes (i.e., survival, recurrence) as key decision-relevant information for patients. Patients prioritized information about relatively severe treatment side-effects and late effects (e.g., blood clot, stroke), whilst professionals prioritized information about effects that occur relatively often (e.g., hair loss, fatigue). Patients specifically wanted to know if the benefit of treatment is worth the negative impact. Both groups prioritized personalized statistics over population-based statistics. Conclusions Some differences between patients and professionals were found in information and communication priorities, specifically related to the different side-effects. It seems worthwhile to precisely address these side-effects in Shared Decision Making concerning adjuvant systemic treatment. Furthermore, it seems important to deliberate together on the question if expected benefit of treatment is worth the potential negative impact for the individual patient.

nursing,oncology
Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field

Islam Eljilany,Ella Castellano,Ahmad A Tarhini

DOI: https://doi.org/10.3390/cancers15164125

2023-08-16

Abstract:The consideration of systemic adjuvant therapy is recommended for patients with stage IIB-IV melanoma who have undergone surgical resection due to a heightened risk of experiencing melanoma relapse and mortality from melanoma. Adjuvant therapy options tested over the past three decades include high-dose interferon-α, immune checkpoint inhibitors (pembrolizumab, nivolumab), targeted therapy (dabrafenib-trametinib for BRAF mutant melanoma), radiotherapy and chemotherapy. Most of these therapies have been demonstrated to enhance relapse-free survival (RFS) but with limited to no impact on overall survival (OS), as reported in randomized trials. In contemporary clinical practice, the adjuvant treatment approach for surgically resected stage III-IV melanoma has undergone a notable shift towards the utilization of nivolumab, pembrolizumab, and BRAF-MEK inhibitors, such as dabrafenib plus trametinib (specifically for BRAF mutant melanoma) due to the significant enhancements in RFS observed with these treatments. Pembrolizumab has obtained regulatory approval in the United States to treat resected stage IIB-IIC melanoma, while nivolumab is currently under review for the same indication. This review comprehensively analyzes completed phase III adjuvant therapy trials in adjuvant therapy. Additionally, it provides a summary of ongoing trials and an overview of the main challenges and future directions with adjuvant therapy.
Melanoma trials that defined surgical management: Brief overview of current/upcoming adjuvant/neoadjuvant trials

Ankit Patel,Joseph Skitzki

DOI: https://doi.org/10.1002/jso.26746

2021-12-13

Journal of Surgical Oncology

Abstract:Adjuvant systemic therapy for cutaneous melanoma has experienced practice-changing shifts over the last decade. The successful results of immunotherapies and targeted therapies in the metastatic setting have allowed for investigative trials of the same therapies in the adjuvant and now neoadjuvant setting, with the potential for improved clinical outcomes in patients with high risk resected Stage III and IV melanoma.

oncology,surgery
Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment

Claus Garbe,Ulrike Keim,Teresa Amaral,Carola Berking,Thomas K. Eigentler,Lukas Flatz,Anja Gesierich,Ulrike Leiter,Rudolf Stadler,Cord Sunderkötter,Thomas Tüting,Jochen Utikal,Uwe Wollina,Lisa Zimmer,Christos C. Zouboulis,Paolo A. Ascierto,Alexander M.M. Eggermont,Jean-Jacques Grob,Axel Hauschild,Lidija Kandolf Sekulovic,Georgina V. Long,Jason J. Luke,Olivier Michielin,Ketty Peris,Dirk Schadendorf,John M. Kirkwood,Paul C. Lorigan

DOI: https://doi.org/10.1200/JCO.22.00202

IF: 45.3

2022-06-18

Journal of Clinical Oncology

Abstract:PURPOSE The first randomized trial of adjuvant treatment with checkpoint inhibitor in stage II melanoma reported a significant reduction in risk of tumor recurrence. This study evaluates two independent data sets to further document survival probabilities for patients with primary stage I and II melanoma. PATIENTS AND METHODS The Central Malignant Melanoma Registry (CMMR) in Germany evaluated 17,544 patients with a primary diagnosis of stage I and II melanoma from 2000 to 2015. The exploratory cohort consisted of 6,725 patients from the Center for Dermato-Oncology at the University of Tübingen, and the confirmatory cohort consisted of 10,819 patients from 11 other German centers. Survival outcomes were compared with published American Joint Committee on Cancer version 8 (AJCCv8) stage I and II survival data. RESULTS For the two CMMR cohorts in stage IA compared with the AJCCv8 cohort, melanoma-specific survival rates at 10 years were 95.1%-95.6% versus 98%; 89.7%-90.9% versus 94% in stage IB; 80.7%-83.1% versus 88% in stage IIA; 72.0%-79.9% versus 82% in stage IIB; and 57.6%-64.7% versus 75% in stage IIC, respectively. Recurrence rates were approximately twice as high as melanoma-specific mortality rates in stages IA-IIA. CONCLUSION The melanoma-specific survival rates in the two CMMR cohorts across stages I and II are less favorable than published in AJCCv8. This has important implications for the consideration of adjuvant treatment in this population.

oncology
Isolated melanoma cells in sentinel lymph node in stage IIIA melanoma correlate with a favorable prognosis similar to stage IB

Teresa Amaral,Lena Nanz,Rudolf Stadler,Carola Berking,Anja Ulmer,Andrea Forschner,Andreas Meiwes,Frederik Wolfsperger,Francisco Meraz-Torres,Eftychia Chatziioannou,Peter Martus,Lukas Flatz,Claus Garbe,Ulrike Leiter

DOI: https://doi.org/10.1016/j.ejca.2024.113912

IF: 10.002

2024-04-01

European Journal of Cancer

Abstract:BACKGROUND: The American Joint Committee on Cancer 8th edition (AJCC v8) defines sentinel lymph nodes (SLN) containing any tumor cells as positive SLN. Consequently, even thin melanomas with isolated tumor cells (ic) in SLN are classified as stage IIIA, making them candidates for adjuvant therapy.OBJECTIVES AND ENDPOINTS: We aimed to evaluate survival outcomes of melanoma stage IIIA (ic) and compare them with stage IIIA with lymph node (LN) metastases > 0.1 mm. Primary endpoints were relapse-free survival (RFS) and distant metastases-free survival (DMFS). Secondary endpoint was melanoma specific survival (MSS).RESULTS: The discovery cohort from the Department of Dermatology, University Hospital Tuebingen, included 237 patients; confirmation cohort included 143 patients from the DeCOG trial. The Tuebingen cohort included 95 patients with stage IIIA (ic) and 142 patients with stage IIIA. The DeCOG trial included 39 patients with stage IIIA (ic) and 104 patients with stage IIIA. In the Tuebingen cohort, 10-year RFS rates for stage IIIA (ic) and IIIA were 84% (95% CI 75-94) and 49% (95% CI 39-59), respectively (p < 0.001). 10-year DMFS rates for stage IIIA (ic) and IIIA were 89% (95% CI 81-97) and 56% (95% CI 45-67), respectively; (p < 0.001). In the DeCOG cohort, 10-year RFS for stage IIIA (ic) and stage IIIA were 88% (95% CI 78-99) and 35% (95% CI 7-62), respectively; (p = 0.009). 10-year DMFS for stage IIIA (ic) and IIIA was 88% (95% CI 77-99) and 60% (95% CI 39-80), respectively (p = 0.061).CONCLUSION: Stage IIIA (ic) melanoma exhibits a prognosis similar to stage IB. Recommendation of adjuvant therapy in Stage IIIA (ic) warrants thorough discussion.

oncology

lnsights into Adjuvant Systemic Treatment Selection for Patients with Stage III Melanoma: Data from the Dutch Cancer Registry

Assessing the use of anti-PD1 monotherapy as adjuvant therapy and determinants of treatment choice in stage III cutaneous melanoma in the US

Disparities in Receipt of Adjuvant Immunotherapy among Stage III Melanoma Patients

Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy

From decision to reflection: understanding the experiences and unmet care needs of patients treated with immunotherapy for melanoma in the adjuvant or metastatic setting

Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry

Treatment of Stage III Resectable Melanoma—Adjuvant and Neoadjuvant Approaches

Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe

The Effect of Neoadjuvant Systemic Therapy on Surgical Outcomes After Lymph Node Dissections for Stage III Melanoma; An Australian Cohort

Sequencing of Immunotherapy and Outcomes in Operable Clinical Stage III Melanoma: A National Cohort Study

Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial

Should I Have Adjuvant Immunotherapy? An Interview Study Among Adults with Resected Stage 3 Melanoma and Their Partners

Adjuvant Therapy for High-Risk Stage II Melanoma: Current Paradigms in Management and Future Directions

Immunotherapy utilization in stage IIIA melanoma: less may be more

Influence of adjuvant therapies on organ-specific recurrence of cutaneous melanoma: A multicenter study on 1383 patients of the prospective DeCOG registry ADOReg

Real‐world outcomes of patients with resected stage III melanoma treated with adjuvant therapies

Information and communication priorities of patients and healthcare professionals in shared decision making regarding adjuvant systemic breast cancer treatment: A survey study

Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field

Melanoma trials that defined surgical management: Brief overview of current/upcoming adjuvant/neoadjuvant trials

Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment

Isolated melanoma cells in sentinel lymph node in stage IIIA melanoma correlate with a favorable prognosis similar to stage IB